Wegovy Solution Auto-injector denials in California external review
In the California DMHC record, independent physician reviewers decided 20 published external-review cases involving Wegovy Solution Auto-injectorand overturned the plan’s denial in 95%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
By condition
| Condition | Decisions | Overturned |
|---|---|---|
| Obesity | 13 | 100% |
What the reviewers wrote
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Wegovy solution auto-injector. Obesity is a multi-causal chronic disease resulting from long-term energy balance with the development of excess adiposity that leads to structural abnormalities, physiological derangements, and functional impairments. Obesity increases the risk of developing other chronic diseases and is associated with further morbidities. The U.S. Food and Drug Administration (FDA) has approved Wegovy for weight loss in patients diagnosed with obesity and a body mass index (BMI) greater than 30 kg/m2.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Wegovy solution auto-injector. Obesity is a disease associated with a significant increase in mortality and health risks, including type 2 diabetes mellitus, hypertension, dyslipidemia, and coronary heart disease. Weight loss in patients with overweight and obesity is associated with a reduction in mortality.
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Wegovy solution auto-injector. The U.S. Food and Drug Administration (FDA) approved Wegovy for weight loss in patients with obesity defined as a body mass index (BMI) of 30 kg/m2, or some patients with a BMI of 27 kg/m2 or greater and one or more weight-associated comorbidity such as dyslipidemia, hypertension, and type 2 diabetes mellitus in addition to a reduced-calorie diet and increased physical activity. Treatment guidelines agree with using pharmacotherapy as an adjunct to lifestyle modification in patients meeting the FDA guidelines. Studies have demonstrated that pharmacotherapy used in combination with lifestyle modifications produces greater and more sustained weight loss when compared with lifestyle modifications alone. In this case, the patient had a current BMI of 25.8 kg/m2.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
Why plans deny Wegovy — and what reviewed cases show
This page covers the Wegovy auto-injector dosage form, which the source data counts separately. The medication, the denial patterns, and the appeal strategy are the same — see the full Wegovy record here.
Wegovy (semaglutide) is FDA-approved for: chronic weight management; reducing the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with established cardiovascular disease and overweight or obesity. An on-label indication can be important evidence when a denial frames the requested use as unproven or cosmetic.
Plan-level weight-loss drug exclusion
Many employer plans exclude the entire “weight-loss drug” benefit category. The denial letter says “not a covered benefit” rather than anything about you. That framing is beatable when the prescription targets a diagnosed condition — obesity is a chronic disease, and Wegovy also carries a cardiovascular indication that has nothing to do with cosmetic weight loss.
BMI documentation gaps
Plans that do cover Wegovy typically require chart-documented BMI plus, at lower BMI levels, a weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, and similar). Denials often turn on the chart not showing the numbers — not on the numbers being wrong.
Step therapy
Plans commonly demand documented failure of a structured lifestyle program or an older, cheaper weight-loss medication first. Reviewers routinely accept a physician's account of prior attempts and reasons alternatives are inappropriate.
Quantity limits and dose-titration denials
Wegovy is titrated stepwise to a maintenance dose. Refill and dose-change requests sometimes get denied as exceeding quantity limits mid-titration — a plumbing problem dressed up as a coverage decision.
If the plan demands you try something else first, request a step-therapy exception: your prescriber attests to prior failures, contraindications, or clinical reasons the preferred alternative is inappropriate. Most states and plan types have a formal exception process with short decision deadlines.
Evidence cited in overturned Wegovy decisions
- Frame obesity as the chronic disease the diagnosis codes say it is — the appeal is about treating a diagnosed condition, not “lifestyle.”
- If cardiovascular disease is in the picture, put the cardiovascular-risk indication front and center: a plan cannot call an FDA-approved cardiac-risk-reduction use cosmetic.
- Document every prior weight-management attempt — programs, medications, outcomes — to preempt the step-therapy rationale.
- Ask the plan for the exact exclusion or criteria language cited; denials that cannot quote plan language tend not to survive review.
The published California record contains 20 external-review decisions involving Wegovy; 95% were overturned. This historical rate does not predict another case. For the full class-wide picture — cross-indication strategy, exclusion language, and the record for every GLP-1 drug — see the GLP-1 denial appeal guide.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Wegovy Solution Auto-injector, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY